OncoMatch/Clinical Trials/NCT07257419
CD45RA-depleted CD19-CAR T Cell Consolidation After TCRαβ+/CD19 B Cell-depleted Haploidentical Hematopoietic Cell Transplantation for Relapsed/Refractory CD19+ ALL and Lymphoma
Is NCT07257419 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments for relapsed pediatric all.
Treatment: Anti-Thymocyte Globulin (Rabbit) · Cyclophosphamide · Fludarabine · Thiotepa · Mesna · Melphalan · Filgrastim · CliniMACS System — The purpose of this study is to learn more about newer methods of transplanting blood cells donated by a partially matched family member to children with high-risk CD19 positive leukemia ALL. Primary Objective: \- To assess the safety and feasibility of combining CD19-CAR(Mem) T cells after TCRαβ+/CD19 depleted haploidentical donor transplantation for pediatric patients with relapsed/refractory CD19+ B-cell malignancies. Secondary Objectives: * To estimate 1-year post-transplant overall survival, event-free survival, and GVHD-free relapse-free survival (GRFS). * To estimate cumulative incidence of engraftment, acute and chronic GVHD, and immune-related adverse events, including CRS and ICANS.
Check if I qualifyExtracted eligibility criteria
Cancer type
Acute Lymphoblastic Leukemia
Acute Myeloid Leukemia
Non-Hodgkin Lymphoma
Multiple Myeloma
Myelodysplastic Syndrome
Chronic Lymphocytic Leukemia
Biomarker criteria
Required: CD19 positive
Prior therapy
Cannot have received: allogeneic hematopoietic cell transplant
Received a prior allogeneic HCT at any time
Lab requirements
Kidney function
creatinine clearance (crcl) or glomerular filtration rate (gfr) ≥ 50 ml/min/1.73m2
Liver function
bilirubin ≤ 3 times the upper limit of normal for age; alt or ast ≤ 5 times the upper limit of normal for age
Cardiac function
left ventricular ejection fraction > 40%, or shortening fraction ≥ 25%
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- St. Jude Children's Research Hospital · Memphis, Tennessee
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify